On January 31, A-share listed Daan Gene released the 2022 full-year performance forecast.

Precision oncology company Guardant Health announced on Monday that FDA has approved its Guardant360 CDx liquid biopsy test as a companion diagnostic.

SQI Diagnostics Inc., a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2022.

Easy Diagnosis released a performance preview on the evening of January 30, expecting 2022 net profit attributable to shareholders of listed companies of CNY4.6 billion to CNY5 billion, an increase of 225.5% to 253.8%; basic earnings per share of about CNY29.99 to CNY32.60.

GE HealthCare (Nasdaq: GEHC), a leading global precision care innovator, reported financial results for the fourth quarter and full year ended December 31, 2022.

Danaher Corporation (NYSE: DHR) (the "Company") announced results for the fourth quarter and full year 2022. All results in this release reflect only continuing operations unless otherwise noted. Net earnings refers to net earnings attributable to common shareholders.

On the evening of January 19, Andon Health Co., Ltd. released the 2022 performance forecast, and it is expected that the company's net profit in 2022 will be 16.5 billion CNY to 17.5 billion CNY, a year-on-year increase of 1715.9% to 1825.95%.

Johnson & Johnson announced results for fourth-quarter and full year 2022.

Abbott announced financial results for the fourth quarter ended Dec. 31, 2022.

VieCure today announced a new collaboration with Labcorp to provide clinicians greater access to precision oncology decision support.

Asep Medical Holdings Inc. is pleased to announce that it has signed a joint venture term sheet with a leading Chinese medical diagnostic company, Sansure Biotech Inc. (Sansure).

Thermo Fisher Scientific and AstraZeneca are collaborating on the development of a new solid tissue and blood-based companion diagnostic (CDx) test for Tagrisso (osimertinib).

Roche and its subsidiary TIB Molbiol on Thursday announced that they have developed a COVID-19 polymerase chain reaction (PCR) test that detects and differentiates the latest variant of concern, XBB.1.5.

Hong Kong Science and Technology Parks (HKSTP) announced a strategic collaboration with Roche, one of the world’s largest pharmaceutical companies, with the aim of leading HK and the Greater Bay Area in becoming a pioneer in life science innovation and to be an example for the region.

Roche subsidiary Foundation Medicine announced on Thursday that it is partnering with Boehringer Ingelheim to develop a companion diagnostic for the pharmaceutical firm's biliary tract cancer drug.